Key facts
- ImmuneBridge’s last known valuation is $25.0M (Jan 2023).
- It has raised $19.7M across 2 recorded rounds; the latest was Early Stage VC ($5.6M) in Mar 2025.
- Notable investors include Pioneer Fund, Insight Partners (New York), Gaingels, Calm Ventures, Endless Frontier Labs — 16 tracked in total.
- ImmuneBridge has filed 2 Form Ds with the SEC since 2023, most recently Apr 2025 ($5.6M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for ImmuneBridge
Funding rounds
2 roundsAbout ImmuneBridge
Developer of allogeneic cellular immunotherapies designed for advancing cancer treatment. The company's immunotherapies utilize proprietary expansion technology to amplify cord blood-derived immune stem cells while maintaining immune multipotency, offering a diverse and consistent cellular source, enabling progenitors with cellular pharmacopeia, and dealing with oncology treatments.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2018
- Employees
- 16
- Website
- immunebridge.com/
- Ownership
- Privately Held (backing)
ImmuneBridge doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ImmuneBridge shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ImmuneBridge in its N-PORT filings yet. We sweep new filings monthly.